[Multiresistant tuberculosis caused by Mycobacterium bovis and human immunodeficiency virus infection. Are there new therapeutic possibilities?].
Valencia
M E
ME
Moreno
V
V
Laguna
F
F
González-Lahoz
J M
JM
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000081:Acetamides / Q000627:therapeutic use*; D000328:Adult; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D000995:Antitubercular Agents / Q000627:therapeutic use*; D019818:Clavulanic Acid / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D018432:Drug Resistance, Multiple; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D000069349:Linezolid; D009163:Mycobacterium bovis; D023303:Oxazolidinones / Q000627:therapeutic use*; D013828:Thioacetazone / Q000627:therapeutic use; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000081:Acetamides; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000995:Antitubercular Agents; D023303:Oxazolidinones; D019818:Clavulanic Acid; D000658:Amoxicillin; D000069349:Linezolid; D013828:Thioacetazone; D007538:Isoniazid